Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer

Stock Information for Nascent Biotech Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nascent Biotech Inc

Nascent Biotech Receives Delinquency Notification Related to its Delayed September 30, 2024 Financial Filing
Nascent Biotech Presents at the July Emerging Growth Conference
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.